Wheat Bread Study: Comparison of the Tolerance of Different Wheat Breads

Non-celiac Gluten Sensitivity Clinical Trial

Official title:

Assessing the Tolerability of Different Types of Wheat Breads in Patients With Suspected Wheat Sensitivity

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06152445
• Other study ID #: ErnMed-Brot-2022
• Status: Recruiting
• Phase: N/A
• Start date: April 19, 2023
• Est. completion date: June 2024

Study information

• Verified date: May 2024
• Source: University of Hohenheim
• Contact: Stephan C Bischoff, Prof.Dr
• Phone: 071145924101
• Email: bischoff.stephan[@]uni-hohenheim.de
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study aims to assess the differences in tolerability of differently manufactured wheat breads in a target group of individuals with suspected wheat sensitivity. Additionally, it will be verified, if the absence of a response to oral exposure to defined bread types is associated with an absence of mucosal changes following CLE-assisted mucosal provocation with bread.

Description:

Nowadays, more than 20% of people in industrialized countries suffer from a food intolerance or food allergy, with wheat and gluten intolerances on the rise. Besides the well-known conditions celiac disease and wheat allergy, another clinical entity called non-celiac wheat sensitivity (NCWS) was described, which is not yet widely understood. Resulting from inconsistent diagnostic criteria the prevalence of NCWS varies from 0.5% to 13%.

Due to the lack of validated diagnostic criteria and/or appropriate biomarkers for diagnosis of NCWS, it can currently only be suspected by exclusion of other diseases. To verify suspected NCWS, a double-blind placebo-controlled food challenge with wheat is recommended. A confocal laser endomicroscopy (CLE) with endoluminal provocation can also provide meaningful results on the individual intestinal mucosal response to specific allergens.

Furthermore, it is as yet unclear whether NCWS is triggered by gluten, FODMAPs, or other wheat components such as α-amylase trypsin inhibitors. Bread manufacturing processes can influence the composition of bread and the presence of possible triggers of intolerance reactions.

This study aims to investigate the tolerability of differently manufactured wheat breads in individuals with suspected NCWS. Additionally, we expect this approach to improve the currently inadequate diagnosis of NCWS, as well as to provide a better understanding of the underlying mechanisms.

Therefore, individuals with suspected NCWS are included in the trial. Five different types of bread will be tested, including 3 differently manufactured wheat breads, a gluten free bread and a gluten free bread with added wheat flour. Aim of this part is to test a possible psychological factor in NCWS symptoms.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 64
• Est. completion date: June 2024
• Est. primary completion date: June 2024
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• Age =18 =75 years

• Signed declaration of consent

• Willingness to adhere to the prescribed diet for the duration of the study

• Chronic gastrointestinal symptoms for at least 6 months

• Anamnestic wheat sensitivity

• No acute or chronic gastrointestinal diseases (e.g. celiac disease / wheat allergy)

• No or stable medication for at least 3 months

• No participation in another clinical trial (current or within the past 30 days)

Exclusion Criteria:

• Taking intestinal therapeutics, antibiotics, immunosuppressants, anti-allergic medication or similar

• Pregnancy / lactation

• Occurrence of relevant diseases (possibly individual decision)

• Revocation of consent

• Concurrent participation in another clinical study

Related Conditions & MeSH terms

• Hypersensitivity
• Non-celiac Gluten Sensitivity
• Wheat Hypersensitivity

Intervention

Other:
• Wheat bread
Different wheat breads

Locations

Country	Name	City	State
Germany	Institute of Nutritional Medicine, University Hospital Schleswig Holstein, Campus Lübeck	Lübeck	Schleswig Holstein
Germany	Institute of Nutritional Medicine, University of Hohenheim	Stuttgart	Baden-Württemberg

Sponsors (2)

Lead Sponsor	Collaborator
University of Hohenheim	University Hospital Schleswig-Holstein

Country where clinical trial is conducted

Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change of IBS-SSS Total Score	IBS-SSS (Irritable Bowel Syndrome - Severity Scoring System) Total score will be assessed with a questionnaire. Severity of gastrointestinal symptoms is shown on a scale from 0 to 500, with values from 75 - < 175 indicating mild symptoms, 175 - 300 moderate symptoms and > 300 severe symptoms.	Study examinations are at baseline, after wash-out phases (week 1, 3, 5) and after bread intervention phases (week 2, 4, 6).
Secondary	Impairment of health-related quality of life assessed by FAQLQ-AF	The impairment of wheat hypersensitivity on quality of life will be assessed with the Food Allergy Quality of Life Questionnaires - Adult Form (FAQLQ-AF). Level of Impairment is shown on a scale from 0 to 35, with higher values indicating severe impairment.	Study examinations are at baseline, after wash out phases (week 1, 3, 5) and after bread intervention phases (week 2, 4, 6)
Secondary	Intestinal permeability	Change of blood, urine and fecal markers to assess intestinal permeability and inflammation after oral administration of bread (Zonulin, LBP, Calprotectin, EDN).	Study examinations are at baseline, after wash out phases (week 1, 3, 5) and after bread intervention phases (week 2, 4, 6)
Secondary	Intestinal inflammation	Change of blood and fecal markers to assess intestinal inflammation after oral administration of bread (Calprotectin, EDN).	Study examinations are at baseline, after wash-out phases (week 1, 3, 5) and after bread intervention phases (week 2, 4, 6)
Secondary	Metabolic alterations	Change in the plasma, urine and fecal metabolome after oral administration of bread (amino acids, biogenic amines)	Study examinations are at baseline, after wash-out phases (week 1, 3, 5) and after bread intervention phases (week 2, 4, 6)